Neural nAChRs PET imaging probes

There have been a number of attempts to study PET radioligands for imaging nicotinic acetylcholine receptors (nAChRs) in the human brain, and the most successful tracers found are radioligands for imaging &agr;4&bgr;2-nAChRs, which is the main cerebral nAChRs subtype. 11C-Nicotine and 2-[18F]FA have been applied in many studies in humans. However, neither is entirely ideal and efforts have been made to develop radioligands with optimized imaging properties. Only a few reports have been published on radioligands for &agr;7-nAChRs imaging, another important cerebral nAChRs subtype. This paper will review the development of PET radioligands for imaging cerebral nAChRs.

[1]  E. Perry,et al.  Molecular analysis of nicotinic receptor expression in autism. , 2004, Brain research. Molecular brain research.

[2]  M. Hajós,et al.  Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. , 2009, Biochemical pharmacology.

[3]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[4]  A. C. Collins,et al.  Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with Schizophrenia , 2000, Neuropsychopharmacology.

[5]  Philippe Faure,et al.  Executive and social behaviors under nicotinic receptor regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Tingley,et al.  In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. , 2005, Bioorganic & medicinal chemistry letters.

[7]  Dean F. Wong,et al.  PET Imaging of High-Affinity α4β2 Nicotinic Acetylcholine Receptors in Humans with 18F-AZAN, a Radioligand with Optimal Brain Kinetics , 2013, The Journal of Nuclear Medicine.

[8]  E. Levin,et al.  Sazetidine-A, a selective α4β2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague–Dawley rats , 2011, Psychopharmacology.

[9]  E. Perry,et al.  Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. , 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[10]  A. Nordberg.  Human nicotinic receptors—Their role in aging and dementia , 1994, Neurochemistry International.

[11]  Edythe D London,et al.  Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. , 2006, Archives of general psychiatry.

[12]  C Martin-Ruiz,et al.  Nicotinic receptor abnormalities in the cerebellar cortex in autism. , 2002, Brain : a journal of neurology.

[13]  C. Stevens.  The acetylcholine receptor , 1980, Nature.

[14]  G. Savage,et al.  Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET , 2008, Psychopharmacology.

[15]  P. Parekh,et al.  Evaluation of 18F-nifene binding to α4β2 nicotinic receptors in the rat brain using microPET imaging , 2011, EJNMMI research.

[16]  W. J. Jackson,et al.  Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo , 1997, Pharmacology Biochemistry and Behavior.

[17]  Philippe Hantraye,et al.  Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  E. Levin,et al.  Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats , 2012, Psychopharmacology.

[19]  J. Bucerius,et al.  In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. , 2006, Nuclear medicine and biology.

[20]  J. Vry,et al.  The Novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  Elliot A. Stein,et al.  Quantification of α4β2* nicotinic receptors in the rat brain with microPET® and 2-[18F]F-A-85380 , 2007, NeuroImage.

[22]  A. Nordberg,et al.  Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. , 1995, Neuroreport.

[23]  P. Brust,et al.  Assessment of α7 nicotinic acetylcholine receptor availability in juvenile pig brain with [18F]NS10743 , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Elliot A Stein,et al.  Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. , 2007, NeuroImage.

[25]  Michele Zoli,et al.  Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain , 1995, Nature.

[26]  B. Långström,et al.  (S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[27]  O. Langer,et al.  Methods to assess tissue-specific distribution and metabolism of drugs. , 2004, Current drug metabolism.

[28]  E. Perry,et al.  Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease , 2000, Neuropharmacology.

[29]  Hiroto Kuwabara,et al.  Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. , 2008, Journal of medicinal chemistry.

[30]  N. Volkow,et al.  6‐[18F]Fluoro‐A‐85380, a new PET tracer for the nicotinic acetylcholine receptor: Studies in the human brain and in vivo demonstration of specific binding in white matter , 2004, Synapse.

[31]  E. Levin.  Nicotinic receptor subtypes and cognitive function. , 2002, Journal of neurobiology.

[32]  A. Wall,et al.  Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET , 2007, Psychopharmacology.

[33]  S. Granon,et al.  [18F]ZW‐104, a new radioligand for imaging α2‐α3‐α4/β2 central nicotinic acetylcholine receptors: Evaluation in mutant mice , 2010, Synapse.

[34]  M. Benwell,et al.  Evidence that Tobacco Smoking Increases the Density of (−)‐[3H]Nicotine Binding Sites in Human Brain , 1988, Journal of neurochemistry.

[35]  Elliot A Stein,et al.  Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380 , 2008, Journal of Nuclear Medicine.

[36]  A. Nordberg,et al.  Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains , 1995 .

[37]  R. Papke,et al.  Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. , 1995, Molecular pharmacology.

[38]  D. Wong,et al.  In vivo specific binding of [3H]1-nicotine in the mouse brain. , 1989, Life sciences.

[39]  S. Potkin,et al.  Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  Victor L Villemagne,et al.  The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. , 2006, Current pharmaceutical design.

[41]  M. Scheunemann,et al.  Radiosynthesis and first evaluation in mice of [(18)F]NS14490 for molecular imaging of α7 nicotinic acetylcholine receptors. , 2013, Bioorganic & medicinal chemistry.

[42]  K. Blennow,et al.  Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. , 1999, Neuroreport.

[43]  J. Changeux,et al.  Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]α‐bungarotoxin binding sites in the brain of Macaca mulatta , 2003, The Journal of comparative neurology.

[44]  M. Pomper,et al.  Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  P. Riederer,et al.  Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome , 2000, Neuroscience Letters.

[46]  Dean F. Wong,et al.  PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with 18F-AZAN, a Radioligand with Improved Brain Kinetics , 2012, The Journal of Nuclear Medicine.

[47]  Marcel Ricard,et al.  Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  M. Boswell,et al.  Smoking produces rapid rise of [11C]nicotine in human brain , 2010, Psychopharmacology.

[49]  C Crouzel,et al.  Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  Johannes Schwarz,et al.  Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. , 2009, Archives of general psychiatry.

[51]  R. Kerwin,et al.  Neuronal Nicotinic Receptors in Dementia with Lewy Bodies and Schizophrenia , 1999, Journal of neurochemistry.

[52]  Kengo Ito,et al.  Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor α7 subtype. , 2010, Nuclear medicine and biology.

[53]  S. Potkin,et al.  Nicotinic alpha4beta2 receptor imaging agents: part II. Synthesis and biological evaluation of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine (18F-nifene) in rodents and imaging by PET in nonhuman primate. , 2006, Nuclear medicine and biology.

[54]  B. Winblad,et al.  Decreased uptake and binding of11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[55]  A Karlin,et al.  Nicotinic acetylcholine receptors. , 1977 .

[56]  A. Beaudet,et al.  Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. , 1997, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[57]  R. Schreiber,et al.  AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors , 2004, Psychopharmacology.

[58]  M. Kassiou,et al.  18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors—In Vitro Binding Properties and PET Studies in Baboons , 2009, Journal of Nuclear Medicine.

[59]  J. Changeux,et al.  Increased neurodegeneration during ageing in mice lacking high‐affinity nicotine receptors , 1999, The EMBO journal.

[60]  D. Donnelly-roberts,et al.  A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand , 1996, Neuropharmacology.

[61]  J. Links,et al.  6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. , 2000, Life sciences.

[62]  Carmen Martin-Ruiz,et al.  Nicotinic receptors in human brain: topography and pathology , 2000, Journal of Chemical Neuroanatomy.

[63]  J. Buccafusco,et al.  Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. , 2007, Biochemical pharmacology.

[64]  G. Savage,et al.  Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study , 2008, Neurobiology of Learning and Memory.

[65]  Mary L. Schneider,et al.  PET Imaging of α4β2* Nicotinic Acetylcholine Receptors: Quantitative Analysis of 18F-Nifene Kinetics in the Nonhuman Primate , 2012, The Journal of Nuclear Medicine.

[66]  John Sharkey,et al.  Nicotine Improves Sustained Attention in Mice: Evidence for Involvement of the α7 Nicotinic Acetylcholine Receptor , 2004, Neuropsychopharmacology.

[67]  J. Schneider,et al.  Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. , 1999, The Journal of pharmacology and experimental therapeutics.

[68]  K. Hashimoto,et al.  Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain. , 2010, Current topics in medicinal chemistry.

[69]  L. Eriksson,et al.  PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo , 1994, Psychopharmacology.

[70]  T. Sharma,et al.  Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) , 2006, Journal of psychopharmacology.

[71]  D. Wong,et al.  Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors. , 2009, PET clinics.

[72]  E. London,et al.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.

[73]  Timothy G. Turkington,et al.  Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine , 2010, Proceedings of the National Academy of Sciences.

[74]  J. Fowler,et al.  Synthesis and evaluation of 6-[(18)F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. , 2000, Nuclear medicine and biology.

[75]  Monique Ernst,et al.  2 [18F]F‐A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  N. Bogdanovic,et al.  Neuronal Nicotinic Receptor Deficits in Alzheimer Patients with the Swedish Amyloid Precursor Protein 670/671 Mutation , 2000, Journal of neurochemistry.

[77]  A. Nordberg,et al.  Neuroreceptor changes in Alzheimer disease. , 1992, Cerebrovascular and brain metabolism reviews.

[78]  J S Fowler,et al.  Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. , 1997, Nuclear medicine and biology.

[79]  G. Savage,et al.  The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2‐[18F]fluoro‐A‐85380 , 2009, Synapse.

[80]  A. Wall,et al.  PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease , 2006, Psychopharmacology.

[81]  B. Christian,et al.  Specific α4β2 nicotinic acetylcholine receptor binding of [F‐18]nifene in the rhesus monkey , 2011, Synapse.

[82]  J. Mukherjee,et al.  Evaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice. , 2013, Nuclear medicine and biology.

[83]  F. Tingley,et al.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. , 2005, Journal of medicinal chemistry.

[84]  Hiroto Kuwabara,et al.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. , 2010, Life sciences.